
    
      This 2-phases study will first evaluate two different doses/schema of avelumab plus
      autologous dendritic cell vaccine (ADC) vaccines, in intention to define which dose is
      effective without hampering safety. Second phase will consist in an standard analysis of
      efficacy and progression free survival. It is expected that 4 Spanish Sites will include
      patients in phase I and 8 Spanish Centers will include patients in the phase II of the study
    
  